↓ Skip to main content

Dove Medical Press

Article Metrics

Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease

Overview of attention for article published in Journal of Asthma and Allergy, August 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#13 of 142)
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
2 news outlets
twitter
5 tweeters

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
12 Mendeley
Title
Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease
Published in
Journal of Asthma and Allergy, August 2016
DOI 10.2147/jaa.s111170
Pubmed ID
Authors

David B Price, Anna Rigazio, Mary Buatti Small, Thomas J. Ferro, Price, David B, Rigazio, Anna, Buatti Small, Mary, Ferro, Thomas J, Thomas J Ferro

Abstract

Using a metered-dose inhaler (MDI) beyond the labeled number of actuations may result in inadequate dosing of medication, which can lead to poor clinical outcomes. This study compared respiratory-related emergency department (ED) visit rates in patients with asthma, chronic obstructive pulmonary disease, or both when they used albuterol MDIs with versus without dose counters. This retrospective study used US claims data to identify patients (ages 4-64 years) with asthma, chronic obstructive pulmonary disease, or both, using albuterol MDIs with or without an integrated dose counter. The study comprised a 1-year baseline period for patient characterization and confounder definition and a 1-year outcome period following the first albuterol prescription. The primary end point was the incidence rate of respiratory-related ED visits, compared using a reduced zero-inflated Poisson regression model. We also compared severe exacerbation rates and rescue medication use. A total of 93,980 patients were studied, including 67,251 (72%) in the dose counter cohort and 26,729 (28%) in the non-dose-counter cohort. The cohorts were broadly similar at baseline (55,069 [59%] female patients; median age, 37 years). The incidence rate of respiratory-related ED visits during the outcome year was 45% lower in the dose counter cohort than in the non-dose-counter cohort (adjusted rate ratio: 0.55; 95% confidence interval: 0.47-0.64). Exacerbation rates and short-acting β-agonist use were similar between cohorts. These findings suggest that dose counter integration into albuterol MDIs is associated with decreased ED visit rates. The presence of integrated dose counters on rescue inhalers can help patients avoid using an empty or near-empty inhaler during exacerbations, thereby ensuring available medication for relief of their symptoms. Integrated dose counters on rescue MDIs could represent a simple and effective tool to improve clinical outcomes during exacerbations, with a potential for cost savings to health care systems.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 3 25%
Student > Bachelor 2 17%
Student > Ph. D. Student 2 17%
Student > Doctoral Student 1 8%
Other 1 8%
Other 3 25%
Readers by discipline Count As %
Medicine and Dentistry 5 42%
Agricultural and Biological Sciences 1 8%
Nursing and Health Professions 1 8%
Psychology 1 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Other 1 8%
Unknown 2 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2018.
All research outputs
#731,667
of 12,576,527 outputs
Outputs from Journal of Asthma and Allergy
#13
of 142 outputs
Outputs of similar age
#24,371
of 260,947 outputs
Outputs of similar age from Journal of Asthma and Allergy
#1
of 5 outputs
Altmetric has tracked 12,576,527 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 142 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,947 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them